What are the payment terms?

We accept LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

What is the lead time for orders?

The average lead time is one month for both peak and off-peak seasons.

Feed Additives Cod-Liver Oil for (Animals Use) GMP ISO

Name: Feed Additives Cod-Liver Oil for (Animals Use) GMP ISO
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1975325252

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$1,600.00

1 Ton

Sample price:US$3.00/kg.Request sample

Product profile

Customization

Available

Certification

ISO, ISO

Shape

Powder

Model NO.

powder

Type

The First Class

Varieties

Growth Promoting Medicine

Component

Chemical Synthetic Drugs

Pharmacodynamic Influential Factors

Repeated Medication

Storage Method

Prevent Throwiing Expired Veterinary Drugs

Transport Package

Bags Buckets

Specification

1kg/bag

Trademark

MOOSUN

Origin

China

HS Code

3004909099

Production Capacity

1500t/Months

Key features

Bone Growth Promotion: Enhances calcium absorption to prevent rickets and growth retardation.

Anti-Stress Formula: Eliminates stress from feed changes, vaccines, and high temperatures.

Improved Egg Quality: Strengthens eggshell smoothness and boosts fertilization rates.

Versatile Application: Suitable for poultry, cattle, calves, goats, and sheep.

OEM and ODM Services: Customization available with 20 R&D engineers and advanced equipment.

ISO Certified Quality: Manufactured under GMP and ISO standards with strict quality control.

Flexible Payment Terms: Accepts LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤11.82h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.